| 货号 | AB-280-NA |
| 别名 | DIRA; ICIL-1RA; IL1F3; IL-1F3; IL1RA; IL-1ra; IL-1ra3; IL1RN; IL-1RN; interleukin 1 receptor antagonist; IRAP; MVCD4 | 全称 | Interleukin 1 Receptor Antagonist |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) |
| 目标/特异性 | Detects human IL‑1ra/IL-1F3 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse IL‑1ra/IL‑1F3, recombinant rat IL-1ra/IL-1F3, recombinant porcine IL‑1ra/IL-1F3, and recombinant equine IL‑1ra/IL-1F3 is observed, and less than 1% cross-reactivity with recombinant human (rh) IL-1a, rhIL-1b, rhIL-18, and rhIL-1H1 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize IL‑1ra/IL‑1F3 inhibition of IL‑1 alpha /IL‑1F1-dependent proliferation in the D10.G4.1 mouse helper T cell line [Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272]. The Neutralization Dose (ND50) is typically 5-10 µg/mL in the presence of 50 ng/mL Recombinant Human IL‑1ra/IL‑1F3, 50 pg/mL Recombinant Human IL‑1 alpha /IL‑1F1 and 1.25 µg/mL concanavalin A. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3557 (Human); 16181 (Mouse); 60582 (Rat); 397499 (Porcine) |
| 纯化方式 | Protein A or G purified |
| 免疫原 | E. coli-derived recombinant human IL‑1ra/IL-1F3 Arg26-Glu177 Accession # P18510 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 1 mg/mL in sterile PBS. |
| 背景 | IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitroandin vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutralization by Human IL‑1ra/IL‑1F3 Antibody. Recombinant Human IL‑1ra/IL‑1F3 (Catalog # 280‑RA) inhibits Recombinant Human IL‑1 alpha /IL‑1F1 (Catalog # 200-LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL‑1 alpha /IL‑1F1 (50 pg/mL) activity elicited by Recombinant Human IL‑1ra/IL‑1F3 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑1ra/IL‑1F3 Polyclonal Antibody (Catalog # AB-280-NA). The ND50 is typically 5-10 µg/mL in the presence of concanavalin A (1.25 µg/mL). |
